Quay Pharma appoints scientific manager

Mark Powell takes on wider technical responsibility

As part of its continuing expansion programme, Quay Pharma, based in Deeside, UK, has appointed Mark Powell as scientific manager. Powell has been with Quay for nearly eight years and was previously in charge of the company’s Analytical Development Group. He has also been elected Honorary Treasurer for the Analytical Division of the Royal Society of Chemistry (RSC).

In his new role, Powell will take on wider technical responsibility and seek to raise further the scientific profile of the company. Quay’s areas of expertise in solid dosage development cover a range of formulation types including lipophilic systems, and are supported by the development of analytical methods for the recovery of API from lipid systems.

As Honorary Treasurer of the RSC Analytical Division, Powell will oversee the Analytical Chemistry Trust Fund, which helps to support research projects, provides travel grants for overseas students and promotes an annual schools competition. The fund is also now introducing a world scholarship programme, helping researchers in developing countries to spend time and gain experience in the UK.

You may also like

Drug Delivery

SGS Quay Pharma receives Queen’s Award for industry

Leading pharmaceutical contract development and manufacturing organisation (CDMO) SGS Quay Pharma has received its Queen’s Award for Enterprise
Finance

SGS makes full-service CDMO acquisition

The investment from SGS is hoped to enhance the development of the company’s work in live biotherapeutics, and its expansion in the United States
Regulatory

Quay establishes biotherapeutic GMP suites

The UK based pharmaceutical outsourcing specialist continues to invest in its work in live biotherapeutics at its facility in Deeside, Flintshire, UK
Research & Development

Quay Pharma to supply promising cancer drug for trial

Quay Pharma has reached an agreement with Redx Pharma to manufacture Redx’s breakthrough cancer treatment drug
Regulatory

Quay Pharma achieves successful US FDA inspection

Underlining the company’s ability to support development projects on a worldwide basis from pre-formulation to initial commercial manufacture
Research & Development

Quay Pharma awarded Eurostars funding for oncology project

Joins a consortium that will work with Hercules Pharmaceuticals to develop a new therapy for breast cancer
Regulatory

Quay Pharma GMP manufacturing suites gain MHRA approval

Pharma outsourcing specialist is now able to make larger non-sterile product batches to support clinical trials and small-scale commercial manufacture
Subscribe now